Antithrombotic Treatment and Its Association with Outcome in a Multicenter Cohort of Transcatheter Edge-to-Edge Mitral Valve Repair Patients

Figures

• 

  Figure 1. Pre- and postprocedural antithrombotic therapy. Sankey diagram illustrating the pre- and postprocedural antithrombotic therapy in successfully treated TEER patients without (A) and with (B) prior indication for oral anticoagulation. APT—antiplatelet therapy, ASA—acetylsalicylic acid, ADP—Adenosin-diphosphate receptor antagonists, SAPT—single antiplatelet therapy, DAPT—dual antiplatelet therapy, NOAC—nonvitamin k antagonist oral anticoagulant, VKA—vitamin k antagonist, OAC—oral anticoagulant.

• 

  Figure 2. Prescription duration of additional antiplatelet therapy after successful TEER. OAC + SAPT—oral anticoagulant + single antiplatelet therapy, OAC + DAPT—oral anticoagulant + dual antiplatelet therapy, DAPT—dual antiplatelet therapy.

• 

  Figure 3. Trends in postprocedural antithrombotic regimens during the study period in patients without (A) and with (B) an indication for oral anticoagulation. (A) Quarterly plot with linear trend line of postprocedural prescription of single antiplatelet therapy (SAPT, blue) and dual antiplatelet therapy (DAPT, red). The percentages refer to all patients without indication for oral anticoagulation (OAC, 160/609). Comparison of prescriptions in first and second half of the study period: SAPT: 7.1% vs. 14.5%, p = 0.1; DAPT: 86.9% vs. 77.6%, p = 0.1. (B) Quarterly plot with linear trend line of postprocedural prescription of an oral anticoagulant (OAC mono, purple), a combination of OAC and SAPT (green) and a combination of OAC and DAPT (purple). Percentages refer to all patients with indication for OAC (449/609). Comparison of prescriptions in first and second half of the study period: OAC mono: 23.1% vs. 40.0%, p = 0.0001; OAC + SAPT: 51.8% vs. 58.0%, p = 0.2; OAC + DAPT: 25.1% vs. 2%, p < 0.0001.

• 

  Figure 4. Trends in prescription of vitamin K antagonists (VKA) and nonvitamin k antagonist oral anticoagulants (NOAC) during the study period. Quarterly plot with linear trend line of prescription of VKA (blue) and NOAC (red). The percentages refer to all patients with indication for oral anticoagulation (449/609). Comparison of prescriptions in the first and second half of the study period: VKA: 72.9% vs. 35.6%, p < 0.0001; NOAC: 27.1% vs. 64.4%, p < 0.0001.